Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

BACKGROUND: Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. MATERIALS, AND METHODS: Hepatic adverse reactions (ARs) were assessed by type and magnitude o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Lewis, James H., Gelderblom, Hans, van de Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia‐Chi, Baba, Hideo A., Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Sarcomas
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100574/
https://ncbi.nlm.nih.gov/pubmed/33289960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13629
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items